Scott Macrae, MD
Ophthalmology · Rochester, NYNPI 1174548671
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $73,750 of the $74,079 with a category attached, or 99.6%. Clerio Vision, Inc accounts for 94.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $70,000 and has fallen 100.0% since, to $22 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $5698.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clerio Vision, Inc$70K
- Bausch & Lomb Americas Inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$664
- Alcon$107
What the payments were for
- Consulting fees$73,750100%
- Food & beverage$3290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clerio Vision, Inc | 1 | $70,000 |
| Bausch & Lomb Americas Inc. | 4 | $3,308 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $664 |
| Alcon | 5 | $107 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lenses$70,000
How this compares
$74,079 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TyrvayaVarenicline Tartrate | 11 | $6,922 |
| Ketorolac Tromethamine | 17 | $335 |
| Gabapentin | 16 | $25 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Rochester
- David KleinmanRochester$730K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.